Impact of CYP2D6 Genetic Polymorphism on Tramadol Pharmacokinetics and Pharmacodynamics

By Siew Hua Gan  

Molecular Diagnosis & Therapy, Vol. 11, Iss. 3, 2007-01 ,pp. : 171-181

Adis International

Access to resources Recommend Favorite

Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed‐function oxidase system, in the metabolism of psychotropic drugs

By  

JOURNAL OF INTERNAL MEDICINE, Vol. 277, Iss. 2, 2015-02 ,pp. : 167-177

John Wiley & Sons Inc

Access to resources Recommend Favorite

CYP2D6*4 polymorphism, tramadol treatment and its clinical impact in patients with postherpetic neuralgia

By Nasare Namita Vilas   Deshmukh Pravin Suryakantrao   Banerjee Basu Dev   Mediratta Pramod Kumari   Ahmed Rafat S   Saxena Ashok Kumar   Bhattacharya Sambit Nath  

Personalized Medicine, Vol. 9, Iss. 4, 2012-06 ,pp. : 371-385

Future Medicine

Access to resources Recommend Favorite

Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital

By Ruañño Gualberto   Villagra David   Rahim Umme Salma   Windemuth Andreas   Kocherla Mohan   Bower Bruce   Szarek Bonnie L   Goethe John W  

Personalized Medicine, Vol. 5, Iss. 6, 2008-11 ,pp. : 579-587

Future Medicine

Access to resources Recommend Favorite

Individualized Therapy for Gastroesophageal Reflux Disease: Potential Impact of Pharmacogenetic Testing based on CYP2C19

By Furuta Takahisa  

Molecular Diagnosis & Therapy, Vol. 16, Iss. 4, 2012-08 ,pp. : 223-234

Adis International

Access to resources Recommend Favorite